|
1
|
Majumdar ID and Weber HC: Biology of
mammalian bombesin-like peptides and their receptors. Curr Opin
Endocrinol Diabetes Obes. 18:68–74. 2011. View Article : Google Scholar
|
|
2
|
Erspamer V: Discovery, isolation, and
characterization of bombesin-like peptides. Ann NY Acad Sci. 547(1
Bombesin- Like): 3–9. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jensen RT, Battey JF, Spindel ER and Benya
RV: International Union of Pharmacology. LXVIII Mammalian bombesin
receptors: Nomenclature, distribution, pharmacology, signaling, and
functions in normal and disease states. Pharmacol Rev. 60:1–42.
2008. View Article : Google Scholar
|
|
4
|
Gonzalez N, Moody TW, Igarashi H, Ito T
and Jensen RT: Bombesin-related peptides and their receptors:
Recent advances in their role in physiology and disease states.
Curr Opin Endocrinol Diabetes Obes. 15:58–64. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spiegelberg BD and Hamm HE: Roles of
G-protein-coupled receptor signaling in cancer biology and gene
transcription. Curr Opin Genet Dev. 17:40–44. 2007. View Article : Google Scholar
|
|
6
|
Preston SR, Miller GV and Primrose JN:
Bombesin-like peptides and cancer. Crit Rev Oncol Hematol.
23:225–238. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Patel O, Shulkes A and Baldwin GS:
Gastrin-releasing peptide and cancer. Biochim Biophys Acta.
1766:23–41. 2006.PubMed/NCBI
|
|
8
|
Martínez A, Zudaire E, Julián M, Moody TW
and Cuttitta F: Gastrin-releasing peptide (GRP) induces
angiogenesis and the specific GRP blocker 77427 inhibits tumor
growth in vitro and in vivo. Oncogene. 24:4106–4113. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jensen JA, Carroll RE and Benya RV: The
case for gastrin-releasing peptide acting as a morphogen when it
and its receptor are aberrantly expressed in cancer. Peptides.
22:689–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou J, Chen J, Mokotoff M and Ball ED:
Targeting gastrin-releasing peptide receptors for cancer treatment.
Anticancer Drugs. 15:921–927. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hohla F and Schally AV: Targeting gastrin
releasing peptide receptors: New options for the therapy and
diagnosis of cancer. Cell Cycle. 9:1738–1741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moody TW, Berna MJ, Mantey S, Sancho V,
Ridnour L, Wink DA, Chan D, Giaccone G and Jensen RT: Neuromedin B
receptors regulate EGF receptor tyrosine phosphorylation in lung
cancer cells. Eur J Pharmacol. 637:38–45. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moody TW, Fagarasan M and Zia F:
Neuromedin B stimulates arachidonic acid release, c-fos gene
expression, and the growth of C6 glioma cells. Peptides.
16:1133–1140. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matusiak D, Glover S, Nathaniel R,
Matkowskyj K, Yang J and Benya RV: Neuromedin B and its receptor
are mitogens in both normal and malignant epithelial cells lining
the colon. Am J Physiol Gastrointest Liver Physiol. 288:G718–G728.
2005. View Article : Google Scholar
|
|
15
|
Ryan RR, Katsuno T, Mantey SA, Pradhan TK,
Weber HC, Coy DH, Battey JF and Jensen RT: Comparative pharmacology
of the nonpeptide neuromedin B receptor antagonist PD 168368. J
Pharmacol Exp Ther. 290:1202–1211. 1999.PubMed/NCBI
|
|
16
|
Tokita K, Hocart SJ, Katsuno T, Mantey SA,
Coy DH and Jensen RT: Tyrosine 220 in the 5th transmembrane domain
of the neuromedin B receptor is critical for the high selectivity
of the peptoid antagonist PD168368. J Biol Chem. 276:495–504. 2001.
View Article : Google Scholar
|
|
17
|
Park HJ, Kim SR, Bae SK, Choi YK, Bae YH,
Kim EC, Kim WJ, Jang HO, Yun I, Kim YM, et al: Neuromedin B induces
angiogenesis via activation of ERK and Akt in endothelial cells.
Exp Cell Res. 315:3359–3369. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park HJ, Kim SR, Kim MK, Choi KS, Jang HO,
Yun I, Bae SK and Bae MK: Neuromedin B receptor antagonist
suppresses tumor angiogenesis and tumor growth in vitro and in
vivo. Cancer Lett. 312:117–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yin JJ, Selander K, Chirgwin JM, Dallas M,
Grubbs BG, Wieser R, Massagué J, Mundy GR and Guise TA: TGF-beta
signaling blockade inhibits PTHrP secretion by breast cancer cells
and bone metastases development. J Clin Invest. 103:197–206. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Casey T, Bond J, Tighe S, Hunter T,
Lintault L, Patel O, Eneman J, Crocker A, White J, Tessitore J, et
al: Molecular signatures suggest a major role for stromal cells in
development of invasive breast cancer. Breast Cancer Res Treat.
114:47–62. 2009. View Article : Google Scholar
|
|
21
|
Liu J, Chen Y, Shuai S, Ding D, Li R and
Luo R: TRPM8 promotes aggressiveness of breast cancer cells by
regulating EMT via activating AKT/GSK-3β pathway. Tumour Biol.
35:8969–8977. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen SC, Kung ML, Hu TH, Chen HY, Wu JC,
Kuo HM, Tsai HE, Lin YW, Wen ZH, Liu JK, et al: Hepatoma-derived
growth factor regulates breast cancer cell invasion by modulating
epithelial-mesenchymal transition. J Pathol. 228:158–169. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo
M, Shao S, Zuo X and Zhao X: Vascular endothelial growth factor
receptor-1 activation promotes migration and invasion of breast
cancer cells through epithelial-mesenchymal transition. PLoS One.
8:e652172013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C,
Yue X, Liu Z, Wu H, Haffty BG, et al: LIF promotes tumorigenesis
and metastasis of breast cancer through the AKT-mTOR pathway.
Oncotarget. 5:788–801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lauring J, Park BH and Wolff AC: The
phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target
in breast cancer. J Natl Compr Canc Netw. 11:670–678.
2013.PubMed/NCBI
|
|
26
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou X, Tan M, Stone Hawthorne V, Klos KS,
Lan KH, Yang Y, Yang W, Smith TL, Shi D and Yu D: Activation of the
Akt/ mammalian target of rapamycin/4E-BP1 pathway by ErbB2
overexpression predicts tumor progression in breast cancers. Clin
Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Fang R, Wang XF, Zhang F, Chen DY,
Zhou B, Wang HS, Cai SH and Du J: Stabilization of Snail through
AKT/GSK-3β signaling pathway is required for TNF-α-induced
epithelial-mesenchymal transition in prostate cancer PC3 cells. Eur
J Pharmacol. 714:48–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cornelio DB, Roesler R and Schwartsmann G:
Gastrin-releasing peptide receptor as a molecular target in
experimental anticancer therapy. Ann Oncol. 18:1457–1466. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kuiper P, Verspaget HW, Biemond I, de
Jonge-Muller ES, van Eeden S, van Velthuysen ML, Taal BG and Lamers
CB: Expression and ligand binding of bombesin receptors in
pulmonary and intestinal carcinoids. J Endocrinol Invest.
34:665–670. 2011.
|
|
31
|
Tsuda T, Kusui T and Jensen RT: Neuromedin
B receptor activation causes tyrosine phosphorylation of p125FAK by
a phospholipase C independent mechanism which requires p21rho and
integrity of the actin cytoskeleton. Biochemistry. 36:16328–16337.
1997. View Article : Google Scholar
|
|
32
|
Ohki-Hamazaki H and Neuromedin B:
Neuromedin B. Prog Neurobiol. 62:297–312. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weigelt B, Peterse JL and van’t Veer LJ:
Breast cancer metastasis: Markers and models. Nat Rev Cancer.
5:591–602. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thompson EW, Newgreen DF and Tarin D:
Carcinoma invasion and metastasis: A role for
epithelial-mesenchymal transition? Cancer Res. 65:5991–5995;
discussion 5995. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Vincent-Salomon A and Thiery JP: Host
microenvironment in breast cancer development:
Epithelial-mesenchymal transition in breast cancer development.
Breast Cancer Res. 5:101–106. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tomaskovic-Crook E, Thompson EW and Thiery
JP: Epithelial to mesenchymal transition and breast cancer. Breast
Cancer Res. 11:2132009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang T, Yuan J, Zhang J, Tian R, Ji W,
Zhou Y, Yang Y, Song W, Zhang F and Niu R: Anxa2 binds to STAT3 and
promotes epithelial to mesenchymal transition in breast cancer
cells. Oncotarget. 6:30975–30992. 2015.PubMed/NCBI
|
|
41
|
Kothari AN, Mi Z, Zapf M and Kuo PC: Novel
clinical therapeutics targeting the epithelial to mesenchymal
transition. Clin Transl Med. 3:352014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang F, Zhou X, Miao X, Zhang T, Hang X,
Tie R, Liu N, Tian F, Wang F and Yuan J: MAGEC2, an
epithelial-mesenchymal transition inducer, is associated with
breast cancer metastasis. Breast Cancer Res Treat. 145:23–32. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seeliger H, Guba M, Kleespies A, Jauch KW
and Bruns CJ: Role of mTOR in solid tumor systems: A therapeutical
target against primary tumor growth, metastases, and angiogenesis.
Cancer Metastasis Rev. 26:611–621. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
McAuliffe PF, Meric-Bernstam F, Mills GB
and Gonzalez-Angulo AM: Deciphering the role of PI3K/Akt/mTOR
pathway in breast cancer biology and pathogenesis. Clin Breast
Cancer. 10(Suppl 3): S59–S65. 2010. View Article : Google Scholar : PubMed/NCBI
|
